O	0	1	A
O	2	12	randomized
O	12	13	,
O	14	20	double
O	20	21	-
O	21	26	blind
O	26	27	,
O	28	35	placebo
O	35	36	-
O	36	46	controlled
O	47	52	trial
O	53	55	of
B-intervention	56	66	preemptive
I-intervention	67	76	analgesia
I-intervention	77	81	with
I-intervention	82	93	bupivacaine
O	94	96	in
O	97	105	patients
O	106	116	undergoing
O	117	127	mastectomy
O	128	131	for
O	132	141	carcinoma
O	142	144	of
O	145	148	the
O	149	155	breast
O	155	156	.

O	157	159	In
O	160	164	this
O	165	176	prospective
O	176	177	,
O	178	188	randomized
O	188	189	,
O	190	197	placebo
O	197	198	-
O	198	208	controlled
O	208	209	,
O	210	216	double
O	216	217	-
O	217	224	blinded
O	225	233	clinical
O	234	239	trial
O	240	242	we
O	243	249	tested
O	250	253	the
O	254	264	hypothesis
O	265	269	that
O	270	280	preemptive
O	281	290	analgesia
O	291	295	with
O	296	307	bupivacaine
O	308	315	applied
O	316	318	in
O	319	322	the
O	323	327	area
O	328	330	of
O	331	334	the
O	335	343	surgical
O	344	352	incision
O	353	355	in
O	356	364	patients
O	365	375	undergoing
O	376	386	mastectomy
O	387	390	for
O	391	397	breast
O	398	404	cancer
O	405	410	would
O	411	417	reduce
B-condition	418	422	post
I-condition	422	423	-
I-condition	423	432	operative
I-condition	433	438	acute
I-condition	439	443	pain
O	444	447	and
O	448	453	would
O	454	460	reduce
O	461	464	the
O	465	471	amount
O	472	474	of
O	475	485	analgesics
O	486	490	used
O	491	497	during
O	498	505	surgery
O	506	509	and
O	510	512	in
O	513	516	the
O	517	521	post
O	521	522	-
O	522	531	operative
O	532	538	period
O	538	539	.

O	540	552	Participants
O	553	557	were
O	558	566	assigned
O	567	571	into
O	572	573	1
O	574	576	of
O	577	578	2
O	579	585	groups
O	585	586	-
O	586	587	-
O	587	591	with
O	592	603	bupivacaine
O	604	611	applied
O	612	614	in
O	615	618	the
O	619	623	area
O	624	626	of
O	627	635	surgical
O	636	644	incision
O	645	647	or
O	648	652	with
B-control	653	660	placebo
O	660	661	.

O	662	664	We
O	665	673	assessed
O	674	677	the
O	678	692	intraoperative
O	693	704	consumption
O	705	707	of
O	708	716	fentanyl
O	716	717	,
O	718	721	the
O	722	735	postoperative
O	736	747	consumption
O	748	750	of
O	751	759	morphine
O	760	769	delivered
O	770	775	using
O	776	777	a
O	778	781	PCA
O	782	788	method
O	788	789	,
O	790	793	and
O	794	797	the
O	798	808	subjective
O	809	813	pain
O	814	823	intensity
O	824	833	according
O	834	836	to
O	837	840	VAS
O	841	846	score
O	847	855	reported
O	856	858	by
O	859	867	patients
O	868	870	in
O	871	874	the
O	875	880	early
O	881	885	post
O	885	886	-
O	886	895	operative
O	896	902	period
O	902	903	.

O	904	907	Out
O	908	910	of
O	911	914	121
O	915	926	consecutive
O	927	932	cases
O	933	942	qualified
O	943	946	for
O	947	957	mastectomy
O	957	958	,
B-total-participants	959	962	112
O	963	968	women
O	969	973	were
O	974	983	allocated
O	984	992	randomly
O	993	995	to
O	996	997	1
O	998	1000	of
O	1001	1002	2
O	1003	1009	groups
O	1009	1010	-
O	1010	1011	-
O	1011	1016	group
O	1017	1018	A
O	1019	1020	(
O	1020	1031	bupivacaine
O	1031	1032	)
O	1033	1036	and
O	1037	1042	group
O	1043	1044	B
O	1045	1046	(
O	1046	1053	placebo
O	1053	1054	)
O	1054	1055	.

O	1056	1059	The
O	1060	1065	final
O	1066	1071	study
O	1072	1077	group
O	1078	1087	comprised
O	1088	1091	106
O	1092	1098	breast
O	1099	1105	cancer
O	1106	1111	cases
O	1111	1112	.

O	1113	1120	Between
O	1121	1124	the
O	1125	1131	groups
O	1131	1132	,
O	1133	1134	a
O	1135	1148	statistically
O	1149	1160	significant
O	1161	1171	difference
O	1172	1175	was
O	1176	1184	observed
O	1185	1189	with
O	1190	1197	respect
O	1198	1200	to
O	1200	1201	:
O	1202	1207	lower
B-outcome	1208	1216	fentanyl
I-outcome	1217	1228	consumption
I-outcome	1229	1235	during
I-outcome	1236	1243	surgery
O	1244	1245	(
O	1245	1246	p
O	1247	1248	=
O	1249	1250	0
O	1250	1251	.
O	1251	1254	011
O	1254	1255	)
O	1255	1256	,
O	1257	1262	lower
B-outcome	1263	1271	morphine
I-outcome	1272	1273	(
I-outcome	1273	1282	delivered
I-outcome	1283	1285	by
I-outcome	1286	1291	means
I-outcome	1292	1294	of
I-outcome	1295	1296	a
I-outcome	1297	1300	PCA
I-outcome	1300	1301	)
I-outcome	1302	1313	consumption
I-outcome	1314	1321	between
I-outcome	1322	1325	the
I-outcome	1326	1327	4
I-outcome	1327	1328	-
I-outcome	1328	1332	12th
I-outcome	1333	1346	postoperative
I-outcome	1347	1352	hours
O	1353	1354	(
O	1354	1355	p
O	1356	1357	=
O	1358	1359	0
O	1359	1360	.
O	1360	1362	02
O	1362	1363	)
O	1364	1367	and
O	1368	1381	significantly
O	1382	1387	lower
B-outcome	1388	1392	pain
I-outcome	1393	1402	intensity
O	1403	1411	assessed
O	1412	1421	according
O	1422	1424	to
O	1425	1428	VAS
O	1429	1434	score
B-outcome	1435	1437	at
I-outcome	1438	1441	the
I-outcome	1442	1445	4th
I-outcome	1446	1449	and
I-outcome	1450	1454	12th
I-outcome	1455	1460	hours
I-outcome	1461	1466	after
I-outcome	1467	1474	surgery
O	1475	1476	(
O	1476	1477	p
O	1478	1479	=
O	1480	1481	0
O	1481	1482	.
O	1482	1485	004
O	1486	1489	and
O	1490	1491	p
O	1492	1493	=
O	1494	1495	0
O	1495	1496	.
O	1496	1498	02
O	1499	1511	respectively
O	1511	1512	)
O	1513	1516	for
O	1517	1520	the
O	1521	1526	group
O	1527	1528	A
O	1529	1537	patients
O	1537	1538	.

O	1539	1549	Preemptive
O	1550	1559	analgesia
O	1560	1571	application
O	1572	1574	in
O	1575	1578	the
O	1579	1583	form
O	1584	1586	of
O	1587	1599	infiltration
O	1600	1602	of
O	1603	1606	the
O	1607	1611	area
O	1612	1614	of
O	1615	1622	planned
O	1623	1631	surgical
O	1632	1641	incisions
O	1642	1646	with
O	1647	1658	bupivacaine
O	1659	1661	in
O	1662	1668	breast
O	1669	1675	cancer
O	1676	1684	patients
O	1685	1695	undergoing
O	1696	1706	mastectomy
O	1707	1716	decreases
O	1717	1721	post
O	1721	1722	-
O	1722	1731	operative
O	1732	1736	pain
O	1737	1746	sensation
O	1746	1747	,
O	1748	1754	limits
O	1755	1758	the
O	1759	1765	amount
O	1766	1768	of
O	1769	1777	fentanyl
O	1778	1782	used
O	1783	1789	during
O	1790	1797	surgery
O	1797	1798	,
O	1799	1802	and
O	1803	1810	reduces
O	1811	1814	the
O	1815	1821	demand
O	1822	1825	for
O	1826	1833	opiates
O	1834	1836	in
O	1837	1840	the
O	1841	1846	hours
O	1847	1851	soon
O	1852	1857	after
O	1858	1865	surgery
O	1865	1866	.
